

## **OHRS Information Sheet Overview of the Operations of the Dana-Farber Cancer Institute Institutional Review Boards**

The Dana-Farber Cancer Institute (DFCI) has seven institutional review boards registered with the United States Department of Health and Human Services (DHHS), Office for Human Research Subjects. These IRBs function on behalf of the Dana-Farber/Harvard Cancer Center and review all cancer-related research conducted under the umbrella of the DF/HCC on behalf of the Beth Israel Deaconess Medical Center; Brigham and Women's Hospital; Children's Hospital Boston; Dana-Farber Cancer Institute; and the Massachusetts General Hospital.

In addition, the DFCI has a Federal Wide Assurance with the DHHS that **requires DFCI IRB review of ALL research, including non-cancer research**, conducted by any DFCI employee.

The following is general information about each of the DFCI IRBs.

1. IRB Panel A - This panel meets the first, third, and fifth Tuesday of each month from 12-2 and reviews new protocols and amendments as well as continuing reviews, serious adverse events, and other events such as deviations, violations and eligibility exceptions that require full board review. This IRB has the expertise to review any matter, if necessary, and does review single patient INDs.
2. IRB Panel B - This panel meets the second and fourth Tuesday of each month from 12-2, alternating with Panel A, and also reviews new protocols and amendments as well as continuing reviews, serious adverse events, and other events such as deviations, violations and eligibility exceptions that require full board review. This IRB has the expertise to review any matter, if necessary, and does review single patient INDs.
3. IRB Panel C - This panel meets the first, third, and fifth Thursday morning of each month from 8-10 and reviews new protocols and amendments as well as continuing reviews, serious adverse events, and other events such as deviations, violations and eligibility exceptions that require full board review. This IRB has the expertise to review any matter, if necessary, and does review single patient INDs.
4. IRB Panel D - This panel meets the first, third, and fifth Monday of every month from 10-12. This panel reviews research that does not involve a clinical intervention. It reviews a diversity of research--it is not limited to minimal risk research--and includes additional procedures conducted for research purposes only, such as blood draws or biopsies; surveys, tissue repositories, and the like. This panel also reviews a number of interventional and non-interventional studies focused on Social and Behavioral research. This panel reviews new protocols, full board continuing reviews, amendments, and other events such as unanticipated problems involving risks to subjects or others that require full board review.

5. IRB Panel E - This panel meets the first, third, and fifth Wednesday of each month from 8-10 and reviews new protocols and amendments as well as continuing reviews, serious adverse events, and other events such as deviations, violations and eligibility exceptions that require full board review. This IRB has the expertise to review any matter, if necessary, and does review single patient INDs.
  
6. IRB Panel F - This panel meets the second and fourth Thursday morning of each month from 8-10, alternating with Panel C, and reviews new protocols and amendments as well as continuing reviews, serious adverse events, and other events such as deviations, violations and eligibility exceptions that require full board review. This IRB has the expertise to review any matter, if necessary, and does review single patient INDs.
  
7. IRB Panel G - This panel meets the first, third, and fifth Tuesday of every month from 8-10. This panel reviews clinical pediatric research.